NCT05028049

Comparison of Remifentanil-induced Postoperative Hyperalgesia Between Patients From Plain Area and Plateau Area

Comparison of Remifentanil-induced Postoperative Hyperalgesia After Gynecological Laparoscopic Surgery Between Patients From the Plain Area and the Plateau Area

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 160 (estimated)
• Sponsor: Tianjin Medical University General Hospital · Academic / Other
• Sex: Female
• Age: 20 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Purpose: 1. To compare the incidence of postoperative hyperalgesia induced by remifentanil in patients undergoing gynecological laparoscopic surgery in plateau and plain areas 2. To compare the peri-operative analgesic requirements of patients in plain and plateau areas

Detailed description

Our research group has been committed to the research of remifentanil-induced hyperalgesia for a long time. In the previous study, it was found that intraoperative infusion of remifentanil (0.3ug/kg•min) \>1h can lead to remifentanil-induced hyperalgesia and the incidence rate is relative high in the plain area. Due to the long-term low pressure and hypoxia of people living in plateau areas, a series of changes will occur in the respiratory and circulatory systems, and their anesthesia management needs to be adjusted accordingly. However, there is no relevant research on whether or not hyperalgesia occurs in people in plateau areas (altitude level \>3000 meters). Therefore, this study hopes to compare the incidence and degree of remifentanil-induced hyperalgesia after gynecological laparoscopic surgery in plain areas and plateau areas.

Conditions

• Pain, Postoperative
• Anesthesia

Interventions

Type	Name	Description
DRUG	Sufentanil injection	Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
DRUG	Remifentanil Hydrochloride	Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
OTHER	plain areas	Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
OTHER	plateau areas	Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)

Timeline

• Start date: 2021-08-30
• Primary completion: 2021-12-15
• Completion: 2021-12-31
• First posted: 2021-08-31
• Last updated: 2021-08-31

Locations

2 sites across 1 country: China